| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 October 1993 | Volume 119 Issue 7 Part 2 | Pages 714-718
The rising incidence of obesity in the United States has given physicians an increased role in its treatment. Although unsupervised programs can produce significant weight losses, the lack of medical supervision increases the potential for health problems. As with other lifestyle changes (for example, smoking cessation and blood pressure control), even minimal physician involvement may enhance outcome. In published clinical trials, the absence of contact with health professionals among control group participants may account in part for their poor success at weight loss or for their weight gain. Smaller trials examining the value of physician advice and encouragement among dieting patients have shown promising results. Physicians should monitor the health of obese and overweight patients during and after weight loss as is appropriate for the patient, depending on caloric levels, rate of weight loss, weight-loss goals, and intercurrent health events. Medical supervision is necessary for patients on very-low-calorie diets, for severely obese patients (body mass index >35), and for patients with other health problems.
Very-Low-Calorie Diets
In 1988, the American Medical Association's (AMA) Council on Scientific Affairs recognized the medical treatment of obesity and established appropriate treatment guidelines [1]. One of these treatments, the very-low-calorie diet (VLCD), typically provides fewer than 800 calories per day, although the American Dietetic Association considers any diet of less than 1000 calories per day to be a very-low-calorie regimen. These diets are attractive to patients because they induce rapid weight loss and because they are easy to follow due to the imposed limitation on the amount and type of food that can be consumed; patients also report no hunger after several days on the program. They are attractive medically because they can improve weight-related disorders and reduce health risks [2].
Medical supervision of VLCD programs is mandatory due to the metabolic characteristics of semistarvation (fatigue, weakness, and lightheadedness) and related changes in vital signs (blood pressure, heart rate, and respiratory rate). These patients often have obesity-related medical complications such as hypertension or diabetes, which require physician monitoring for appropriate adjustment of medication [3]. Very-low-calorie diets are associated with only minor complications when administered to carefully selected patients by physicians trained in their use [4, 5]. The importance of careful patient selection is shown by attrition rates of 33% to 50% among patients receiving VLCDs [6]. As identified by the Council on Scientific Affairs [1], the Medical Letter on Drugs and Therapeutics [7], and various investigators [8], not all VLCDs have the same metabolic effects, protein-sparing ability, or safety.
At the Technology Assessment Conference, Wadden [9] reviewed the results of clinical trials that used VLCDs and noted that "approximately 90 percent of persons treated by a VLCD and behavior modification will attain a weight loss of this magnitude (9.1 kg or more) and 50 percent a weight loss of 18.2 kg or more". He went on to conclude that "efforts are needed to identify methods of making available. the intensive treatment approach developed in research trials"an intensive approach that, without exception, involves a supervising physician.
Low-Calorie Diets
The AMA's Council on Scientific Affairs also recognized the use of low-calorie diets (LCDs), which provide more than 800 calories per day [1]. Low-calorie diets represent the most common and, when compliance is monitored, safest treatment of obesity. Compliance with LCDs usually ensures that weight loss does not exceed 0.5% to 1.0% of initial body weight per week, which is recommended as safe and acceptable by the U.S. Dietary Guidelines [10].
When monitored by a physician and supervised by a registered dietitian or clinical nutritionist, the LCD should be sufficient for most patients to promote a 10% to 15% weight loss over 10 to 20 weeks. This level of weight loss results in most of the health benefits associated with weight loss [11, 12]; without documented weight maintenance success, additional weight losses of more than 10% must be justified by the supervising physician [13]. Due to the level of carbohydrate intake [14], these regimens are rarely associated with the consequences of starvation metabolism sometimes encountered with VLCDs.
Physicians must become involved in obesity treatment when the patient has concurrent disease or other risk factors for fatal complications. Overweight persons have an increased risk for morbidity and death that is proportional to their degree of obesity and that also increases with age and the presence of additional disease [15]. A body mass index (BMI) of 25 to 30 kg/m2 (independent of concurrent illness) may be described as incurring low risk, 30 to 35 as moderate risk, 35 to 40 as high risk, and anything greater than 40 as very high risk [16]; an excellent nomogram is also available for use [17].
In general, however, medically unsupervised dieting is safe provided that the patient does not have any concurrent medical problems and is not severely overweight (BMI >35) and provided that the weight loss does not exceed 1% of initial body weight per week [13]. In addition, the diet macro- and micronutrient composition must be safe and balanced [18]. Deviation from recommended dietary guidelines (for example, too little fat, no meal with at least 10 g fat, excessive protein) can lead to medical problems including the formation of gallstones [19, 20].
Persons planning to lose weight on their own should see their physician for a baseline physical examination to identify any underlying diseases and to discuss weight loss strategies and goals (Table 1). In addition to completing a thorough examination and medical history, physicians should collect information on the patient's nutritional history as well as on the waist and hip circumferences (to monitor reduction in risk through changes in waist-to-hip ratio). Weight loss should not exceed 1% of body weight per week; if weight is lost faster, the physician should suspect unsupervised use of a VLCD (conversely, weight loss at less than 0.5% of body weight per week may indicate low compliance with lifestyle changes). Physician visits should subsequently be scheduled after any 10% change in body weight (loss or gain) and whenever a change in health status is noted. If fatigue, muscle weakness, lightheadedness, or new health problems arise, the physician should be notified promptly [3]. METHODS FOR VOLUNTARY WEIGHT LOSS AND CONTROL: NATIONAL INSTITUTES OF HEALTH TECHNOLOGY ASSESSMENT CONFERENCE
Comparison of Medically Supervised and Unsupervised Approaches to Weight Loss and Control
Unlike other chronic diseases that require physician supervision (for example, diabetes mellitus, hypertension, and cardiovascular disease), obesity is usually treated without medical intervention. Only recently have the metabolic disorders associated with clinically significant obesity, such as syndrome X and its individual components (hyperinsulinemia, dyslipidemia, hypertension, and hyperuricemia), alerted health care professionals to the need for medical intervention in the treatment of obesity. This report reviews recommendations and published results for both medically supervised and unsupervised treatment in clinical trials using dietary interventions. The role of physicians in the prevention of weight gain is also discussed.
Recommendations for Medically Supervised Programs
![]()
Recommendations for Medical Monitoring of Unsupervised Programs
![]()
At any given time, an estimated 65 million Americans diet to lose weight, and many of these persons participate in commercial programs or consume over-the-counter products. Recent reports of gallstone formation (requiring cholecystectomies), cardiac arrhythmias, and even death have generated concern regarding the safety of some unsupervised commercial programs [3]. To a large extent, the lack of medical supervision and the lack of guidelines to indicate when medical supervision is necessary are responsible for diet-related morbidity and death.
|
Published Comparison of Medically Supervised and Unsupervised Programs
|
|---|
Table 2 lists statistics comparing weight change results of dietary intervention (medically supervised) and control (unsupervised) patients enrolled in studies designed to examine the effect of weight loss on health measures such as blood pressure, glucose control, and lipid profile. In addition to the significantly greater weight loss noted among patients in the intervention group, most controls gained weight. Because potential participants must be willing to accept any of the trial interventions, those volunteering for these studies are most likely to be interested in losing weight. Stamler and colleagues [22] specifically excluded persons expressing an unwillingness to change. At baseline, those randomized to the control group could be assumed to have equal motivation to lose weight as those randomized to intervention groups (although, in some cases, controls are specifically told not to diet or to make other lifestyle changes, and in other studies they are considered to be "self-help" patients, particularly if their participation in screening and enrollment has heightened their awareness of the value of weight control in improving health or if they receive educational materials for home use).
|
In one study, we compared the outcome of 187 obese hypertensive patients using medically supervised VLCD and LCD programs [23]. Those receiving the VLCD (a protein-sparing modified fast) experienced a 17% reduction in initial body weight, whereas those receiving the LCD (a balanced deficit diet) lost 12% of initial body weight (Table 3). During the 6 months of active maintenance (medically supervised), patients regained only 5% (VLCD) and 2% (LCD) of their body weight. For the next 18 months, patients had no clinic contact and came in for milestone visits only. During this period, patients regained weight at a faster rate, maintaining only 41% (VLCD) and 38% (LCD) of their initial weight loss at 18 months.
|
In a study of 49 overweight hypertensive patients, Ramsay and colleagues [24] compared the effectiveness of physician advice alone, physician advice plus written and oral diet instructions (given by a physician), and physician referral to a dietitian (who was unaware of the study) for instruction on body weight and blood pressure. After this encounter (advice, diet sheet, dietitian), management during the 1 year of follow-up was routine and voluntary until the second and last data collection visits (9 to 15 months after the baseline visit). The results indicated that intervention of any kind had some effect, with one third of all patients losing 6 kg or more 1 year after randomization (Table 4).
|
Other Evidence That Physician Supervision Makes a Difference
|
|---|
Recent reviews [28] of the doctor-patient relationship indicate that it provides many opportunities to encourage behavioral change, to reinforce positive changes (for example, improved dietary practices, increased activity, and steady weight loss and control), and to encourage use of community resources through appropriate referrals to outside agencies and facilities (for example, local registered dietitian, acceptable supervised and unsupervised weight-loss programs). Patients appear to be willing to listen to advice from their physicians, with some authorities reporting that people expect such advice on maintaining health [29].
In addition to providing guidance to weight-loss efforts among overweight and obese patients, physicians can help prevent the development of obesity by alerting patients at risk for weight gain during routine medical examinations. The incidence of substantial weight gain during a 18-year period has been shown to be highest among adults 25 to 34 years old (particularly women and those who are already overweight) and to decrease with increasing age [30].
Specific data regarding the success and cost-effectiveness of physician involvement in weight-loss attempts should come from the Trial of Antihypertensive Interventions and Management (TAIM) study. The investigators reported that a weight loss of 4.5 kg or more lowered blood pressure in a manner similar to low-dose drug therapy and potentiated drug effect [31]. These 6-month results and the accompanying summary of other hypertensive trials suggest that physicians can assist in producing the modest amount of weight loss (that is, 10%) required to improve health.
Direction for Future Research
|
|---|
Author and Article Information
|
|---|
|
|
|---|
References
|
|---|
|
|
|---|
1. Treatment of obesity in adults. Council on Scientific Affairs. JAMA. 1988; 260:2547-51.
2. Anderson JW, Hamilton CC, Brinkman-Kaplan V. Benefits and risks of an intensive very-low-calorie diet program for severe obesity. Am J Gastroenterol. 1992; 87:6-15.
3. Wadden TA, Van Itallie TB, Blackburn GL. Responsible and irresponsible use of very-low-calorie diets in the treatment of obesity. JAMA. 1990; 263:83-5.
4. Palgi A, Read JL, Greenberg I, Hoeffer MA, Bistrian BR, Blackburn GL. Multidisciplinary treatment of obesity with a protein-sparing modified fast: results in 668 outpatients. Am J Public Health. 1985; 75:1190-4.
5. Holmes MD, Zysow B, Delbanco TL. An analytic review of current therapies for obesity. J Fam Pract. 1989; 28:610-6.
6. Wadden TA, Foster GD, Letizia KA, Stunkard AJ. A multicenter evaluation of a proprietary weight reduction program for the treatment of marked obesity. Arch Intern Med. 1992; 152:961-6.
7. Formula diets for obesity. Med Lett Drugs Ther. 1989; 31:22-3.
8. Davis PG, Phinney SD. Differential effects of two very low calorie diets on aerobic and anaerobic performance. Int J Obes. 1990; 14: 779-87.
9. Wadden TA. Evidence for success of caloric restriction in weight loss and control: summary data from clinical research studies. In: Scannell K, Dilch SM. Methods for Voluntary Weight Loss and Control. Bethesda, Maryland: U.S. Dept. of Health and Human Services; 1992:64-74.
10. United States. Congress. Senate. Committee on Appropriations. Subcommittee on Agriculture, Rural Development, and Related Agencies. Dietary Guidelines for Americans. Washington, DC: U.S. Government Printing Office; 1990.
11. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes. 1992; 16:397-415.
12. Kanders BS, Forse RA, Blackburn GL. Obesity. In: Conn HF, Rakel RE. Conn's Current Therapy. Philadelphia: W.B. Saunders; 1991.
13. Kanders BS, Blackburn GL. Health consequences of therapeutic weight loss: reducing primary risk factors. In: Wadden TA, Van Itallie TB; eds. The Treatment of Morbid Obesity. New York: Guilford Press; 1992:213-30.
14. Blackburn GL, Bray GA; eds. Management of Obesity by Severe Caloric Restriction. Littleton, Massachusetts: PSG; 1985.
15. Wadden TA, Stunkard AJ, Brownell KD. Very low calorie diets: their efficacy, safety, and future. Ann Intern Med. 1983; 99:675-84.
16. Bray GA. Pathophysiology of obesity. Am J Clin Nutr. 1992; 55(2 Suppl):488S-94S.
17. Bray GA. Classification and evaluation of the obesities. Med Clin North Am. 1989; 73:161-85.
18. Weinsier RL, Wadden TA, Ritenbaugh C, Harrison GG, Johnson FS, Wilmore JH. Recommended therapeutic guidelines for professional weight control programs. Am J Clin Nutr. 1984; 40:865-72.
19. Klawansky S, Chalmers TC. Fat content of very low-calorie diets and gallstone formation (Letter). JAMA. 1992; 268:873.
20. Sichieri R, Everhart JE, Roth H. A prospective study of hospitalization with gallstone disease among women: role of dietary factors, fasting period, and dieting. Am J Public Health. 1991; 81:880-4.
21. Cohen MD, D'Amico FJ, Merenstein JH. Weight reduction in obese hypertensive patients. Fam Med. 1991; 23:25-8.
22. Stamler R, Stamler J, Gosch FC, Civinelli J, Fishman J, McKeever P, et al. Primary prevention of hypertension by nutritional-hygienic means. Final report of a randomized, controlled trial. JAMA. 1989; 262:1801-7.
23. Blackburn GL, Jones CT, Kanders BS, Lavin PT, Greenberg I. Non-pharmacological treatment of hypertension (HTN), in the obese hypertensive (Abstract). Circulation. 1988; 78:II-568.
24. Ramsay LE, Ramsay MH, Hettiarachchi J, Davies DL, Winchester J. Weight reduction in a blood pressure clinic. Br Med J. 1978; 2:244-5.
25. Li VC, Coates TJ, Ewart CK, Kim Y. The effectiveness of smoking cessation advice given during routine medical care: physicians can make a difference. Am J Prev Med. 1987; 3:81-6.
26. Cummings SR, Rubin SM, Oster G. The cost-effectiveness of counseling smokers to quit. JAMA. 1989; 261:75-9.
27. Inui TS, Yourtee EL, Williamson JW. Improved outcomes in hypertension after physician tutorials. A controlled trial. Ann Intern Med. 1976; 84:646-51.
28. Green LW. Prevention and health education. In: Last JM; ed. Public Health and Preventive Medicine. 12th ed. East Norwalk, Connecticut: Appleton-Century-Crofts; 1986.
29. Williamson PS, Driscoll CE, Dvorak LD, Garber KA, Shank JC. Health screening examinations: the patient's perspective. J Family Pract. 1988; 27:187-92.
30. Williamson DF, Kahn HS, Remington PL, Anda RF. The 10-year incidence of overweight and major weight gain in US adults. Arch Intern Med. 1990; 150:665-72.
31. Wassertheil-Smoller S, Blaufox MD, Oberman AS, Langford HG, Davis BR, Wylie-Rosett J. The Trial of Antihypertensive Interventions and Management (TAIM) study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. Arch Intern Med. 1992; 152:131-6.
32. Task Force to Establish Weight Loss Guidelines. Toward Safe Weight Loss. East Lansing, Michigan: Center for Health Promotion, State of Michigan Department of Public Health; 1990.
33. Task Force on the Treatment of Obesity. Report of the Task Force on the Treatment of Obesity. Ottawa, Ontario: Health Services and Promotion Branch, Health and Welfare; 1991.
34. Kaplan RM, Wilson DK, Hartwell SL, Merino KL, Wallace JP. Prospective evaluation of HDL cholesterol changes after diet and physical conditioning programs for patients with type II diabetes mellitus. Diabetes Care. 1985; 8:343-8.
35. Rocchini AP, Katch V, Schork A, Kelch RP. Insulin and blood pressure during weight loss in obese adolescents. Hypertension. 1987; 10:267-73.
36. The effect of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I. JAMA. 1992; 267:1213-20.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||